Oncology

The clinical trial success in canines may have broader implications for applicability.

A single-center experience at a tertiary medical center precision medicine clinic provides insight.

Within this care model, pharmacists can serve an important role in caring for patients, whether it is identifying adverse medication interactions or pushing patients to seek additional support.

Providing clinical trials at community locations allows patients with travel restrictions to access novel treatments that are typically studied academic institutions.

Not only did the Navya-Patient Preference Tool help patients with decision-making, but groups who used the tool were more likely to receive their preferred form of surgery.

Little progress has been made in developing treatments that can help to stop Ewing sarcomas from spreading or coming back.

Oncolytic polymers may be the answer to circumventing therapeutic resistance in cancer treatment.

The results also indicate an association with increased risk of colorectal and noncolorectal gastrointestinal cancers as body mass index increases over time.

Up to 81% of patients with cancer take medications to treat their other comorbidities.

The manager of patient support services at St. Luke’s Cancer Center discusses the significance of Reaching Out for Healthy Women and how female patients can receive support from this initiative.

Lack of awareness, cultural beliefs, and physician preferences may influence whether minority patients receive palliative care during metastatic breast cancer treatment.

Diversity in patient populations, including age, race, ethnicity, and underrepresented regions, have increased in early-phase National Cancer Institute-sponsored trials.

Intravenous immunoglobulin could potentially be given throughout the duration of anti-BCMA bispecific antibody therapy for the treatment of multiple myeloma.

Cancer mortality rates increased by 3.3 deaths per 100,000 individuals and was higher for historically minoritized populations.

Ongoing studies utilizing large-scale health databases that incorporate environmental, lifestyle, biological, and phenotypic data may provide insight that leads to better cancer prevention and treatment.

Artificial intelligence has helped ensure a data-driven methodology for evaluating eligibility criteria for clinical trials, facilitating more inclusive trial design.

Craig Dolan, PharmD, MBA, BSPharm discusses the role of the pharmacist, how the pharmacy profession has changed, and what is to come in the field.

Expert explains how the role of pharmacists in myelofibrosis treatment has evolved significantly over the past decade.

The origins of American Pharmacists Month trace back to October 1925, when radio stations nationwide aired special programming for a week to spotlight the pharmacy profession.

The MARIPOSA study evaluated amivantamab-vmjw (Rybrevant; Janssen Pharmaceutical) in combination with lazertinib compared to osimertinib and compared to lazertinib monotherapy in the first-line treatment of EGFR-mutated non–small cell lung cancer.

The study authors suggest that after initiating alpelisib, patients should be proactive by improving glycemic status to reduce the risk of developing hyperglycemia.

Ruben A. Mesa, MD, FACP, discusses the results of the SIMPLIFY-1 and MOMENTUM trials and how the data led to the approval of momelotinib to treat intermediate or high-risk myelofibrosis in adult patients with anemia.

Lutetium Lu177 dotatate demonstrated significant and clinically meaningful progression-free survival for those with SSTR-positive and inoperable midgut neuroendocrine tumor.

The combined enfortumab vedotin-ejfv and pembrolizumab treatment is recommended for patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing therapy.

Bosutinib (Bosulif) is indicated to treat pediatric patients with Philadelphia chromosome–positive chronic-phase chronic myelogenous leukemia that is newly diagnosed, resistant, or intolerant to previous therapy.

Investigators reported that enfortumab vedotin-ejfv (Padcev; Astella Pharma Inc, Seagen Inc) in combination with pembrolizumab (Keytruda; Merck & Co Inc) met the dual primary endpoints of overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

As the resident medication experts, pharmacists are qualified to answer any medication-related questions and conduct data analyses.

Datopotamab deruxtecan (Dato-DXd; AstraZeneca, Daiichi Sankyo) also demonstrated improved overall survival compared to chemotherapy.

Nivolumab has also demonstrated efficacy in immunotherapy-based combinations for the treatment of certain types of melanoma and bladder cancers.